Production equipment for tobacco endogenous antiviral preparation

Abstract

The utility model discloses production equipment for a tobacco endogenous antiviral preparation. The production equipment comprises a screw elevator, a mixer, a crusher, a cyclone separator, a pulse dust collector and a storage bin, the discharge end of the screw elevator is communicated with the mixer; a discharge port of the mixer is communicated with a feed port of the crusher; a discharge port of the crusher is communicated with a feed port pipeline of the cyclone separator; and a powder outlet of the cyclone separator is communicated with the storage bin through a pipeline. The production equipment for the tobacco endogenous antiviral preparation processed by the equipment can avoid the problem of inactivation of the production equipment for the tobacco endogenous antiviral preparation.

Description

Technical Field

[0001] This application relates to the field of tobacco endogenous antiviral agent production technology, and in particular to a production equipment for tobacco endogenous antiviral agents. Background Technology

[0002] Tobacco endogenous antiviral agents are a novel biological agent against tobacco mosaic virus. They can effectively inactivate the virus in tobacco plants, reduce viral activity, alleviate the impact of the virus on tobacco plants, and enhance the resistance of tobacco plants to the virus.

[0003] The raw materials for tobacco endogenous antiviral agents are powdered substances. This reduces the activity of the active ingredients in the resulting agents, affecting their efficacy or rendering them ineffective in achieving their intended antiviral effect. Consequently, this hinders the promotion and use of the reagent.

[0004] The information disclosed in the background section is intended only to enhance the understanding of the overall background of this utility model and should not be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art. Utility Model Content

[0005] This application provides a production equipment for tobacco endogenous antiviral agents to address the above-mentioned technical problems, which can avoid the inactivation of the obtained tobacco endogenous antiviral agents, and the field comprehensive control efficacy of the obtained agents can reach 70-80%.

[0006] This application provides a production equipment for tobacco endogenous antiviral agents, including: a screw conveyor, a mixer, a pulverizer, a cyclone separator, a pulse dust collector, and a storage silo; the discharge end of the screw conveyor is connected to the mixer; the discharge port of the mixer is connected to the feed port of the pulverizer.

[0007] The discharge port of the crusher is connected to the inlet pipe of the cyclone separator; the powder outlet of the cyclone separator is connected to the storage silo pipe.

[0008] The air outlet of the cyclone separator is connected to the feed inlet of the pulse dust collector; the powder outlet of the pulse dust collector is connected to the storage silo.

[0009] The air outlet of the pulse dust collector is connected to the air inlet of the storage silo.

[0010] Preferably, the cyclone separator separates 80% of the solid powder of the tobacco endogenous antiviral agent produced;

[0011] The pulse dust collector separates the remaining solid powder of tobacco endogenous antiviral agents obtained during production;

[0012] Cyclone separators and pulse dust collectors are connected in series to cool down tobacco endogenous antiviral agents and preserve their activity.

[0013] Preferably, it includes: a support frame; and a storage bin mounted on the support frame.

[0014] Preferably, it includes: a silo wall vibration motor; the silo wall vibration motor is installed on the outer wall of the storage silo.

[0015] Preferably, it includes: an automatic packaging machine and a screw feeder; the feed end of the screw feeder is connected to the discharge end of the storage bin; the discharge end of the screw feeder is connected to the automatic packaging machine.

[0016] Preferably, it includes: a discharger and a collection hopper; the discharger is installed on the powder outlet of the cyclone separator; the discharge outlet of the discharger is connected to the collection hopper pipeline.

[0017] Preferably, it includes: a dust collection hopper; the dust collection hopper is disposed on the dust outlet of the pulse dust collector and is connected to the pulse dust collector.

[0018] Preferably, it includes: a powder feeding pipe, a powder pump, and a powder suction pipe; the powder suction pipe is connected to a collection hopper and a dust collection hopper respectively; the powder outlet of the powder suction pipe is connected to the feed end of the powder pump; the powder outlet of the powder pump is connected to the feed inlet of the powder feeding pipe; and the powder outlet of the powder feeding pipe is connected to a storage silo.

[0019] Preferably, it includes: multiple valves; the valves are installed on the pipeline connecting the mixer and the crusher; the valves are installed on the pipeline connecting the collecting hopper and the unloader.

[0020] The beneficial effects that this application can produce include:

[0021] 1) The tobacco endogenous antiviral agent production equipment provided in this application produces tobacco endogenous antiviral agents with good water solubility and full retention of activity, which can effectively exert antiviral effects. It is suitable for tobacco fields and can effectively reduce the incidence of viral diseases. It can further improve the field control efficacy by 70% to 80% while retaining the activity of tobacco endogenous antiviral components, thereby effectively ensuring the normal functioning of prevention and control and ensuring the effectiveness of promotion and use. Attached Figure Description

[0022] Figure 1 A front view schematic diagram of an apparatus for processing tobacco endogenous antiviral agents in at least one embodiment provided in this application;

[0023] Figure 2 A three-dimensional schematic diagram of the equipment for processing tobacco endogenous antiviral agents in at least one embodiment provided in this application;

[0024] Legend:

[0025] 1. Screw Conveyor; 2. Mixer; 3. Crusher; 4. Powder Conveying Pipe; 5. Cyclone Separator; 6. Dust Pipe; 7. Pulse Dust Collector; 8. Dust Pipe; 9. Storage Bin; 10. Support; 11. Bin Wall Vibration Motor; 12. Automatic Packaging Machine; 13. Screw Feeder; 14. Powder Conveying Pipe; 15. Powder Pump; 16. Dust Collection Hopper; 17. Suction Pipe; 18. Collection Hopper; 19. Unloader. Detailed Implementation

[0026] To make the objectives, technical solutions, and advantages of the embodiments of this utility model clearer, the technical solutions of the embodiments of this utility model will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this utility model, not all embodiments. The components of the embodiments of this utility model described and shown in the accompanying drawings can typically be arranged and designed in various different configurations.

[0027] Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the claimed invention, but merely to illustrate selected embodiments of the invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention.

[0028] Technical means not detailed in this application and not used to solve the technical problems of this application are all set according to common general knowledge in the field, and multiple common general knowledge setting methods can be implemented.

[0029] See Figures 1-2 The production equipment for tobacco endogenous antiviral agents provided in this application includes: a screw conveyor 1, a mixer 2, a pulverizer 3, a powder conveying pipe 4, a cyclone separator 5, a dust pipe 6, a pulse dust collector 7, a dust pipe 8, and a storage silo 9.

[0030] A receiving hopper is provided at the feed end of the screw conveyor 1, and the discharge end of the screw conveyor 1 is connected to the mixer 2 so that the operator can add various materials into the mixer 2. The bottom of the mixer 2 is provided with a discharge port, which is set directly opposite the feed port of the crusher 3 so as to crush the premixed materials. After the materials enter the crusher for crushing, a 200-mesh tobacco endogenous antiviral preparation is obtained. The powder is blown to the cyclone separator 5 by the air pressure generated by the crusher 3, and the gas then enters the pulse dust collector 7 for solid-gas separation. In this process, the powder material can be cooled and the moisture content can be controlled, which is beneficial to protect the active substances and avoid deactivation.

[0031] The pneumatic conveying device used here is a commonly used device in this field and will not be described in detail here.

[0032] In one specific embodiment, the cyclone separator 5 separates 80% of the solid powder product of the tobacco endogenous antiviral agent produced, which is then discharged to the collection hopper 18 via the unloader 19. The outlet of the cyclone separator 5 is connected to the inlet pipe of the pulse dust collector 7 through the dust pipe 6, thereby effectively collecting the remaining powder material in the airflow and avoiding material waste. The pulse dust collector 7 is used to recover most of the remaining powder material.

[0033] In one specific embodiment, a dust collection hopper 16 is provided on the dust outlet of the pulse dust collector 7 to collect powder materials. The collected materials are then transferred into the storage silo 9 through pipelines.

[0034] In one specific embodiment, a dust collection hopper 16 is provided on the powder outlet of the cyclone separator 5 to collect powdery materials. The collected materials are then transferred into the storage silo 9 through a pipeline.

[0035] In one specific embodiment, the exhaust port of the pulse dust collector 7 is connected to the storage silo 9 via a dust pipe 8, and the dust is transported to the silo for storage through a closed pipeline. This prevents dust from flying and polluting the environment. To ensure the air pressure balance inside and outside the storage silo 9, an exhaust port is provided on the top of the storage silo 9, and a filter screen is installed on the exhaust port to prevent dust from being generated during exhaust.

[0036] In one specific embodiment, it further includes: a support 10; and a storage bin 9 mounted on the support 10. This is to prevent moisture absorption by the production equipment for the tobacco endogenous antiviral agent, which could lead to impaired activity.

[0037] In one specific embodiment, it includes: a bin wall vibration motor 11; the bin wall vibration motor 11 is installed on the outer wall of the storage bin 9 to ensure smooth material feeding during unloading.

[0038] In one specific embodiment, it includes: an automatic packaging machine 12 and a screw feeder 13; the feeding end of the screw feeder 13 is connected to the discharging end of the storage bin 9; the discharging end of the screw feeder 13 is connected to the automatic packaging machine 12, so as to automatically unload and package the tobacco endogenous antiviral preparation.

[0039] In one specific embodiment, it includes: a discharger 19 and a collection hopper 18; the discharger 19 is provided on the powder outlet of the cyclone separator 5; the discharge outlet of the discharger 19 is connected to the collection hopper 18 via a pipeline.

[0040] In one specific embodiment, the system includes: a powder feeding pipe 14, a powder pump 15, and a powder suction pipe 17; the powder suction pipe 17 is connected to a collection hopper 18 for receiving solid powder from the cyclone separator 5 and a dust collection hopper 16 for receiving powder from the pulse dust collector 7; the powder outlet of the powder suction pipe 17 is connected to the feed end of the powder pump 15; the powder outlet of the powder pump 15 is connected to the feed inlet of the powder feeding pipe 14; and the powder outlet of the powder feeding pipe 14 is connected to the storage silo 9, thereby realizing the directional conveying of the powder obtained by the cyclone separator 5 and the pulse dust collector 7.

[0041] In one specific embodiment, the system includes: multiple valves; these valves are installed on the pipeline connecting the mixer 2 and the crusher 3, and are used to control the material conveying to the crusher. Simultaneously, electric valve control technology is employed to control the feed rate for continuous production, preventing uneven particle size distribution after crushing and improving the uniformity of particle size to meet the 200-mesh requirement. Valves are also installed on the pipeline connecting the collection hopper 18 and the unloader 19, and are used to control the material conveying to the storage silo 9.

[0042] In one specific embodiment, the pulverizer 3 is a high-energy pulverizer.

[0043] In one specific embodiment, the pipe connecting the crusher 3 and the cyclone separator 5 is a closed pipe to prevent dust leakage and flying.

[0044] In one specific embodiment, the dust suction pipe 17 is a closed pipe to prevent dust leakage and flying.

[0045] Tobacco endogenous antiviral agents produced are stored in storage silo 9 to balance and homogenize production capacity. Screw conveying technology is used to transport the material from the storage silo to the packaged products.

[0046] The tobacco endogenous antiviral agent processed by this equipment consists of: tobacco endogenous antiviral components: potassium humate: diatomaceous earth: zinc sulfate in a mass ratio of 1:0.02-0.07:0.05-0.15.

[0047] Composition: 0.15–0.25; Mesh size of tobacco endogenous antiviral components: 80–100 mesh;

[0048] The processing method includes the following steps:

[0049] Step S1: Tobacco endogenous antiviral components: potassium humate: diatomaceous earth: zinc sulfate are added to the mixer in proportion and premixed. After premixing for 10-40 minutes, the mixture is pulverized in the pulverizer at a rate of 5-15 kg / min. The pulverized mixture is then conveyed to the cyclone separator for gas-solid separation. The resulting powder is collected as the tobacco endogenous antiviral agent.

[0050] Step S2: The gas obtained from solid-gas separation enters the pulse dust collector for further solid-gas separation, and the solid powder is collected as an endogenous antiviral agent for tobacco.

[0051] The moisture content of the production equipment for the obtained tobacco endogenous antiviral preparation is less than 5%; the material temperature in the premixing and pulverizing stages is measured in real time to be less than 30℃; and the particle size of the production equipment for the obtained tobacco endogenous antiviral preparation is more than 80% 200 mesh particles.

[0052] The endogenous antiviral component used was prepared by the method in Example 1 of CN2021 1 1534831.3. The specific preparation method is as follows: The tobacco sample was obtained from waste materials in the cigarette manufacturing process, including tobacco stems; tobacco leaves were not suitable. 50 kg of tobacco was pulverized and extracted twice with 70% methanol and 0.025 mol / L hydrochloric acid solution, 3 hours each time. The extracts were combined, filtered, and concentrated under reduced pressure to obtain 5 kg of extract. The pH of the extract was adjusted to 10 with ammonia water, and the extract was loaded onto a macroporous adsorption resin D-101 column at a flow rate of (2 mL / min * column diameter (cm) / 1.5) equal to 6 times the weight of the concentrate. The column was washed with pure water for 2 BV, and then with 3 BV of 30% ethanol solution.

[0053] Impurities were washed away at a flow rate of 2 mL / min * column diameter (cm) / 1.5, followed by elution with 3.4 BV of 80% ethanol at a flow rate of 2 mL / min * column diameter (cm) / 1.5. The eluent was then distilled under reduced pressure until its density reached 1.10–1.105 g / cm³ at 20°C. The concentrate was dried using a centrifugal spray dryer with an inlet air temperature set at 170–190°C and an outlet air temperature at 90–92°C. The inlet air volume and liquid flow rate were adjusted according to the equipment parameters. The dried extract was then pulverized and passed through a 100-mesh sieve to obtain the tobacco endogenous antiviral component.

[0054] The tobacco endogenous antiviral agent prepared by this method has good water solubility and retains all its activity, thus effectively exerting its antiviral effect. It is suitable for use in tobacco fields and can effectively reduce the incidence of viral diseases. It can further improve the field control efficacy while retaining the activity of tobacco endogenous antiviral components, thereby effectively ensuring the normal functioning of prevention and control and guaranteeing the effectiveness of its promotion and use.

[0055] The efficacy testing process and methods are described in Example 7 of CN2021 1 1534831.3. The overall field efficacy of this formulation can reach 70%–80%.

[0056] In one specific embodiment, the apparatus used in the production of this method

[0057] In one specific embodiment, the tobacco endogenous antiviral preparation is composed of: tobacco endogenous antiviral components: potassium humate: diatomaceous earth: zinc sulfate in a mass ratio of 1:0.07:0.15:0.25; the mesh size of the tobacco endogenous antiviral components is 80-100 mesh;

[0058] The processing method includes the following steps:

[0059] Step S1: Add the tobacco endogenous antiviral components: potassium humate, diatomaceous earth and zinc sulfate to the mixer in proportion and premix. After premixing for 40 minutes, the mixture is put into the pulverizer for pulverization. The pulverization process is carried out at 5 kg / min. After that, the mixture is conveyed into the cyclone separator for gas-solid separation. The resulting powder is collected as the production equipment for tobacco endogenous antiviral preparations.

[0060] Step S2: The gas obtained from solid-gas separation enters the pulse dust collector for further solid-gas separation, and the solid powder is collected as an endogenous antiviral agent for tobacco.

[0061] The moisture content of the production equipment used for the obtained tobacco endogenous antiviral preparation is less than 5%; the material temperature during the premixing and pulverizing stages is measured in real time to be below 30℃; and the particle size of the obtained tobacco endogenous antiviral preparation is more than 80% 200-mesh particles. Temperature measurement can be performed using a handheld infrared thermometer to measure the temperature of the mixed and pulverized materials. If the temperature exceeds the limit, circulating water can be used to cool the materials to ensure that the temperature during the premixing and pulverizing stages meets the requirements. A circulating water jacket can be installed on the side wall of the pulverizing chamber shell of the pulverizer 3, depending on the required ambient temperature, and circulating water can be introduced to control the temperature during the premixing and pulverizing stages. Similarly, a circulating water jacket can be installed on the side wall of the mixing chamber shell of the mixer 2.

[0062] In one specific embodiment, the tobacco endogenous antiviral preparation is composed of: tobacco endogenous antiviral components: potassium humate: diatomaceous earth: zinc sulfate in a mass ratio of 1:0.02:0.05:0.15; the mesh size of the tobacco endogenous antiviral components is 80-100 mesh;

[0063] The processing method includes the following steps:

[0064] Step S1: Tobacco endogenous antiviral components: potassium humate: diatomaceous earth: zinc sulfate are added to the mixer in proportion and premixed. After premixing for 10 minutes, the mixture is put into the pulverizer for pulverization. The pulverization process is carried out at 15 kg / min. After that, the mixture is conveyed into the cyclone separator for gas-solid separation. The resulting powder is collected as tobacco endogenous antiviral preparation.

[0065] Step S2: The gas obtained from solid-gas separation enters the pulse dust collector for further solid-gas separation, and the solid powder is collected as an endogenous antiviral agent for tobacco.

[0066] The moisture content of the production equipment used to produce the obtained tobacco endogenous antiviral preparation is less than 5%; the material temperature in the premixing and pulverizing stages is measured in real time to be less than 30℃; and the particle size of the obtained tobacco endogenous antiviral preparation is more than 80% of 200-mesh particles.

[0067] Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A production apparatus for a tobacco endogenous antiviral preparation, characterized by comprising: It comprises: a screw elevator (1), a mixer (2), a pulverizer (3), a cyclone separator (5), a pulse dust collector (7), a storage bin (9); the discharge end of the screw elevator (1) is connected with the mixer (2); the discharge port of the mixer (2) is connected with the feed inlet of the pulverizer (3); the discharge port of the pulverizer (3) is connected with the feed inlet of the cyclone separator (5) through a pipeline; the powder outlet of the cyclone separator (5) is connected with the storage bin (9) through a pipeline; the gas outlet of the cyclone separator (5) is connected with the feed inlet of the pulse dust collector (7) through a pipeline; the powder outlet of the pulse dust collector (7) is connected with the storage bin (9) through a pipeline; the gas outlet of the pulse dust collector (7) is connected with the gas inlet of the storage bin (9) through a pipeline.

2. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by, The cyclone separator (5) separates 80% of the solid powder of the tobacco endogenous antiviral preparation produced; The pulse dust collector (7) separates the remaining part of the solid powder of the tobacco endogenous antiviral preparation produced; The cyclone separator (5) and the pulse dust collector (7) are connected in series to cool and preserve the activity of the tobacco endogenous antiviral preparation.

3. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by It comprises: a support (10); the storage bin (9) is installed on the support (10).

4. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by It comprises: a bin wall vibration motor (11); the bin wall vibration motor (11) is arranged on the outer wall of the storage bin (9).

5. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by It comprises: an automatic packaging machine (12) and a screw feeder (13); the feed end of the screw feeder (13) is connected with the discharge end of the storage bin (9); the discharge end of the screw feeder (13) is connected with the automatic packaging machine (12).

6. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by It comprises: a discharger (19) and a collection hopper (18); the discharger (19) is arranged on the powder outlet of the cyclone separator (5); the discharge port of the discharger (19) is connected with the collection hopper (18) through a pipeline.

7. The production apparatus for a tobacco endogenous antiviral agent according to claim 6, characterized by It comprises: a dust collection hopper (16); the dust collection hopper (16) is arranged on the powder outlet of the pulse dust collector (7) and is connected with the pulse dust collector (7).

8. The production apparatus for a tobacco endogenous antiviral agent according to claim 7, characterized by It comprises: a powder feeding pipe (14), a powder pump (15) and a powder suction pipe (17); the powder suction pipe (17) is connected with the collection hopper (18) and the dust collection hopper (16) respectively; the powder outlet of the powder suction pipe (17) is connected with the feed end of the powder pump (15); the powder outlet of the powder pump (15) is connected with the feed inlet of the powder feeding pipe (14); the powder outlet of the powder feeding pipe (14) is connected with the storage bin (9).

9. The production apparatus for a tobacco endogenous antiviral agent according to claim 1, characterized by It comprises: a plurality of valves; the valves are arranged on the pipeline connecting the mixer (2) and the pulverizer (3); the valves are arranged on the pipeline connecting the collection hopper (18) and the discharger (19).

Images